CBAYライブシグナル | Getagraph.comで利益を最大化

買う 57530 min ago

@ $32.47

発行日: 21 3月 2024 @ 03:01

リターン: 0.03%

前回のシグナル: 3月 20 - 03:47

前回のシグナル: 売る

リターン: -0.03 %

Live Chart Being Loaded With Signals

Commentary (22 3月 2024 @ 05:00):

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases...

Stats
本日の出来高	0.00
平均出来高	4.16M
時価総額	3.73B
EPS	$0 ( 2024-03-21 )
次の収益日	( $-0.320 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-32.81
ATR14	$0.00700 (0.02%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-22	Loewy Caroline M	Sell	30 000	Employee Stock Option (right to buy)
2024-03-22	Loewy Caroline M	Sell	15 000	Employee Stock Option (right to buy)
2024-03-22	Loewy Caroline M	Sell	7 500	Employee Stock Option (right to buy)
2024-03-22	Loewy Caroline M	Sell	16 000	Employee Stock Option (right to buy)
2024-03-22	Loewy Caroline M	Sell	27 705	Employee Stock Option (right to buy)

INSIDER POWER
-97.48
Last 100 transactions
Buy: 127 470 \| Sell: 9 848 383

ボリューム相関

長: -0.17 (neutral)

短: -0.63 (weak negative)

Signal:(46.979) Neutral

Cymabay Therapeutics Inc 相関

10 最も正の相関
XPDB	0.96
ROCL	0.956
HWEL	0.955
IXAQ	0.953
GDNR	0.953
ARTEU	0.952
VMGA	0.952
FNVT	0.952
AVAC	0.951
PWUP	0.951

10 最も負の相関
RMRM	-0.983
ASPS	-0.952
BFC	-0.945
EVLO	-0.943
CLFD	-0.942
CREG	-0.941
YJ	-0.941
STAB	-0.941
SYBT	-0.939
MMAT	-0.936

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Cymabay Therapeutics Inc 相関 - 通貨/商品

0.00
( neutral )

0.12
( neutral )

Cymabay Therapeutics Inc 財務諸表

Annual	2023
収益:	$31.07M
総利益:	$30.39M (97.81 %)
EPS:	$-0.990

FY	2023
収益:	$31.07M
総利益:	$30.39M (97.81 %)
EPS:	$-0.990

FY	2022
収益:	$0
総利益:	$-710 000 (0.00 %)
EPS:	$-1.350

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.304

Financial Reports:

No articles found.

Cymabay Therapeutics Inc

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.